Fact-checked by Grok 2 weeks ago

Addictive behavior

Addictive behavior is defined as a persistent of compulsive engagement with substances or rewarding activities, such as or excessive use, that overrides and continues despite foreseeable harm, development, and symptoms upon cessation. This arises from neuroadaptations in the brain's mesolimbic reward pathway, where repeated exposure to potent stimuli triggers surges of that reinforce learning and shift behavior from impulsive choice to automatic . Empirical and reveal heightened sensitivity to addiction-related cues, diminished prefrontal inhibitory function, and prioritization of short-term rewards over long-term well-being, affecting an estimated 10-15% of the global population across substance and behavioral forms. Key characteristics include cycles of escalation, craving, and relapse vulnerability, driven by causal interactions of genetic predispositions, environmental triggers, and reinforcement mechanisms rather than isolated moral failings or purely . While institutional sources often frame as an irreversible chronic disease, first-principles analysis of evidence supports viewing it as a modifiable learned response amenable to behavioral interventions that restore natural reward sensitivity.

Definition and Conceptual Foundations

Core Definition and Characteristics

Addictive behavior constitutes a involving repetitive engagement in rewarding activities or substance use that becomes compulsive, persisting despite demonstrable harm to physical , psychological , social relationships, or occupational functioning. This pattern reflects a to resist impulses, drives, or temptations to perform acts harmful to the self or others, often preceded by mounting tension and followed by transient pleasure, gratification, or relief. Such behaviors are clinically significant when they produce distress or substantial interference in personal areas of life, as codified in frameworks like the , which groups non-substance-related addictive behaviors (e.g., gaming disorder) under disorders due to addictive behaviors. Central characteristics, as delineated in biopsychosocial models of , encompass six core components applicable to both substance and behavioral forms: salience, wherein the activity increasingly dominates thoughts, feelings, and behaviors to the exclusion of other interests; mood modification, involving use of the behavior to achieve emotional escape, , or ; and , marked by the need for escalating intensity or frequency to attain the original effect. Additional defining features include , manifesting as dysphoric moods, irritability, or physiological discomfort upon cessation (even absent overt in behavioral cases); , encompassing intrapersonal guilt or alongside interpersonal disputes and of responsibilities; and , characterized by repeated unsuccessful efforts to or cease the despite awareness of its consequences. These elements underpin the loss of behavioral , differentiating addictive patterns from adaptive habits through empirical observation of impaired volition and escalation toward dysfunction. Preoccupation or intense cravings further amplify this cycle, rendering alternative pursuits subordinate and fostering a narrowed on and .

Distinction from Compulsion and Habit

Addictive behaviors are defined by the pursuit of substances or activities despite foreseeable harm, marked by intense cravings, , and symptoms that perpetuate the cycle. This process involves neuroadaptations in the brain's reward circuitry, leading to a loss of behavioral flexibility where actions override rational . In contrast, habits form through repeated of stimulus-response associations, becoming automatic and cue-triggered without the same level of motivational or adverse . Habits, such as routine drinking, can be modified or extinguished by altering environmental cues or incentives, as they lack the entrenched hedonic drive and negative seen in . Compulsions, as in obsessive-compulsive disorder (OCD), entail repetitive actions or mental rituals aimed at alleviating distress from intrusive obsessions, often recognized by the individual as irrational and ego-dystonic—meaning they conflict with the person's values and generate anxiety when resisted. Unlike addictive behaviors, which initially provide pleasure or relief through dopamine-mediated reward anticipation and may feel ego-syntonic until consequences accumulate, OCD compulsions lack this positive reinforcement and instead serve to prevent perceived catastrophe, with no escalation via . Neuroimaging reveals OCD compulsions linked to hyperactive orbitofrontal-striatal circuits emphasizing error detection and habit-like rigidity without reward hijacking, whereas shifts from ventral striatal goal-directed seeking to dorsal striatal habitual responding overlaid with persistent craving. While advanced can manifest compulsive-like inflexibility—resembling unyielding habits that resist suppression—empirical studies indicate true affects only a of individuals with substance use disorders, often late-stage, and differs phenomenologically from OCD by retaining appetitive over pure anxiety reduction. Habits contribute to all three but are distinguished in by their integration with escalated incentive salience, where cues elicit compulsive approach despite devaluation of outcomes. This triad highlights causal distinctions: habits via associative learning, compulsions via avoidance of obsession-fueled , and via reward dysregulation fostering maladaptive persistence.

Neurobiological Underpinnings

Brain Reward System Alterations

The 's reward system, primarily the mesolimbic dopamine pathway originating in the (VTA) and projecting to the , evolved to reinforce survival behaviors through phasic release in response to natural rewards like or social interaction. In addictive behaviors, exogenous substances or compulsive actions elicit supraphysiological surges—often 2-10 times greater than natural rewards—hijacking this circuitry and fostering intense reinforcement. This hyperactivation disrupts , shifting the system from adaptive signaling to maladaptive prioritization of the addictive stimulus. Chronic exposure induces neuroadaptations, including downregulation of D2/D3 receptors in the , reducing receptor density by up to 20-30% in and users as measured by (PET). This blunts responsiveness to non-addictive rewards, contributing to and , where escalating doses are required to achieve prior levels. Synaptic remodeling, such as strengthened glutamatergic inputs to the , further entrenches cue-induced craving by associating environmental triggers with release. Functional magnetic resonance imaging (fMRI) and studies reveal hypoactivation in reward regions during natural reward processing in addicts; for instance, cocaine users show diminished ventral striatal responses to monetary incentives compared to controls. Structural changes, including reduced gray matter volume in the and orbitofrontal regions, impair over reward-seeking, with longitudinal data indicating these persist even after prolonged . These alterations extend to behavioral addictions like , where similar mesolimbic hypofrontality correlates with compulsive risk-taking. Anti-reward mechanisms, involving extended hyperactivity, emerge as compensatory responses, generating dysphoric states that drive to alleviate withdrawal-induced rather than pursue . Overall, these changes reflect allostatic dysregulation, where the reward setpoint recalibrates around the addictive agent, perpetuating cycles of dependence.

Genetic and Neurochemical Influences

Twin and family studies, including designs, consistently demonstrate a substantial genetic contribution to addictive behaviors, with heritability estimates for substance use disorders ranging from 40% to 70%. Meta-analyses of twin studies further support this, showing moderate to high genetic influences across various addictions, such as alcohol use disorder with around 50-60%, though environmental factors interact to modulate expression. These estimates derive from comparisons of monozygotic and dizygotic twins, where shared genetic variance explains a larger proportion of than shared environment alone. Candidate gene studies have identified polymorphisms in dopamine-related genes as key risk factors. The DRD2 gene, encoding the D2 , features the Taq1A polymorphism (rs1800497), where the A1 is associated with reduced receptor density, diminished reward sensitivity, and elevated risk for , , and dependence; this occurs in approximately 20-30% of populations and correlates with poorer treatment outcomes. Similarly, the COMT Val158Met polymorphism (rs4680) influences catabolism in the , with the Met linked to slower breakdown, heightened , and increased vulnerability to and addiction by altering executive control over reward-seeking. Genome-wide association studies (GWAS) confirm DRD2's role in broader liability, mapping to pathways of reward processing, though effect sizes remain small (odds ratios ~1.1-1.5) and polygenic risk scores explain only 5-10% of variance. Neurochemically, addictive behaviors arise from dysregulated signaling in the mesolimbic dopamine pathway, particularly involving the and , where substances acutely elevate transients by 200-1000% above baseline, fostering . Chronic exposure induces tolerance via downregulated D2 receptors and hypofrontality, reducing endogenous efficacy and driving compulsive use to restore hedonic tone; this is evidenced by showing 20-30% receptor occupancy deficits in abstinent addicts. Glutamatergic adaptations in the core amplify cue-induced craving, with escalated trafficking strengthening habits independent of . Serotonergic systems, via 5-HT2A and transporter genes, modulate and , with deficits contributing to cross-addiction risks, as low serotonin turnover correlates with escalated intake in animal models. Genetic variants often converge on these neurochemical pathways; for instance, DRD2 A1 carriers exhibit blunted responses to stimuli, predisposing to external reward dependence, while COMT variants exacerbate prefrontal imbalances that impair over glutamatergic drives. Epigenetic modifications, such as of DRD2 promoters, further link heritable risks to environmental triggers, though longitudinal human data remain limited. These influences underscore as a disorder of perturbed in reward neurocircuitry rather than mere moral failing, with implications for targeting modulators like for OPRM1 carriers.

Etiology and Risk Factors

Genetic Predispositions

Twin and studies consistently estimate the of substance use disorders (SUDs) at approximately 40-60%, indicating that genetic factors account for a substantial portion of vulnerability to addictive behaviors across substances like , , and illicit drugs. A of such studies for use disorder (AUD) specifically yielded a of 0.49 (95% CI: 0.43-0.53), with similar ranges observed for other addictions, though estimates vary by substance—e.g., 0.39 for dependence and up to 0.72 for . These figures derive from comparing concordance rates in monozygotic versus dizygotic twins, which control for shared environments and highlight additive genetic influences, though shared genetic liabilities extend across SUDs, as evidenced by overlapping polygenic risk scores. Candidate gene studies have identified polymorphisms in dopamine-related genes as key contributors to addiction risk, particularly through alterations in reward processing. The DRD2 gene, encoding the D2 , features the Taq1A polymorphism (A1 ), which reduces receptor density and is associated with diminished reward sensitivity, elevating risk for AUD, , , and ; this variant occurs more frequently in affected individuals and correlates with outcomes. Similarly, the COMT gene, which regulates breakdown via , shows variants (e.g., Val158Met) that influence prefrontal levels, with low-activity alleles linked to heightened and vulnerability in SUDs, including and addiction. Other implicated loci include OPRM1 () for substance-specific effects and serotonin transporter genes like , which interact with DRD2 to modulate craving intensity. Genome-wide association studies (GWAS) reinforce a polygenic , identifying hundreds of variants with small individual effects but cumulative impact; for instance, a 2024 analysis mapped AUD to 66 genes, including DRD2 and novel loci affecting neurodevelopment and , explaining only 5.6-10% of SNP-based despite twin estimates near 50%, underscoring missing from rare variants or gene-environment interactions. Shared genetic signals across SUDs, such as those in and pathways, suggest a generalized liability to addictive behaviors rather than substance-specific , with polygenic scores predicting cross-disorder in cohorts. While these findings emanate from large-scale, peer-reviewed consortia minimizing bias, earlier candidate gene associations faced replication challenges due to small samples, emphasizing the need for rigorous, hypothesis-free approaches like GWAS for .

Personality Traits and Psychological Vulnerabilities

Impulsivity, characterized by a tendency to act without forethought or consideration of consequences, emerges as a core trait conferring vulnerability to addictive behaviors across substances and behavioral addictions. Meta-analytic evidence indicates that higher precedes and predicts the onset of substance use disorders (SUDs), with effect sizes ranging from moderate to large in longitudinal designs tracking adolescents into adulthood. This trait disrupts delay discounting, wherein individuals overly favor immediate rewards, a mechanism observed in studies linking hypoactivity to both trait and escalation. Sensation-seeking, defined as the pursuit of varied, novel, complex, and intense sensations and experiences, independently heightens risk by motivating initial experimentation with addictive stimuli. Reviews of developmental studies show that elevated sensation-seeking in early correlates with subsequent , with heritability estimates around 0.4-0.6 suggesting partial genetic underpinnings that interact with pubertal reward sensitivity. Unlike , which impairs inhibition, sensation-seeking drives approach behaviors toward high-risk activities, as evidenced by stronger associations in behavioral addictions like , where odds ratios for high scorers exceed 2.0 in prospective cohorts. Within the personality framework, low —encompassing poor self-discipline, organization, and goal-directed behavior—consistently predicts broader addictive liability, with meta-analyses reporting inverse associations (r ≈ -0.20 to -0.30) for , , , and illicit drugs. High , marked by emotional instability and , further amplifies vulnerability through pathways, as individuals prone to anxiety or distress show elevated odds of SUD onset (OR ≈ 1.5-2.0), though familial confounds partially attenuate these links in twin designs. Low , involving reduced and , also correlates with addiction proneness, particularly in interpersonal contexts facilitating enabling environments, but effects are smaller (r ≈ -0.10). Psychological vulnerabilities extend to traits like and low distress tolerance, which undermine coping and precipitate reliance on addictive agents for affect regulation. Empirical data from clinical samples reveal that individuals with high trait —difficulty identifying and describing emotions—exhibit twofold higher rates of comorbid addictions, driven by impaired interoceptive awareness rather than mere symptom overlap. traits (Machiavellianism, , ) show selective links to offline addictions, with strongly predicting persistence via pathways, as per cross-sectional surveys of treatment-seeking populations. These traits do not constitute a monolithic "" but represent heritable endophenotypes that causally contribute to risk when proximal triggers align, per evidence from genetically informative models.

Environmental and Developmental Triggers

Environmental factors significantly contribute to the initiation and escalation of addictive behaviors, with meta-analytic evidence indicating a moderate-to-large of 0.61 for environmental influences on tendencies. exposure, for instance, heightens vulnerability by altering neurobiological pathways, including dysregulation of the hypothalamic-pituitary-adrenal axis and enhanced sensitivity to drug cues, as demonstrated in preclinical models where stressed animals exhibit increased self-administration of substances like . Socioeconomic disadvantage, characterized by low and limited resources, correlates with higher prevalence of substance use disorders; a study of U.S. young adults found that childhood family below the median was associated with 1.5- to 2-fold increased of heavy and marijuana use in adulthood, independent of parental education. Peer influence emerges as a proximal trigger, particularly during , where longitudinal data reveal that perceived peer substance use predicts initiation, with a of 47 studies reporting a pooled of r = 0.25 for on adolescent drug use, stronger for behavioral conformity than direct . Family and community environments further modulate through modeling and availability. Parental substance use doubles the odds of initiation compared to non-using , per longitudinal studies tracking children into adulthood. Neighborhood deprivation, including high and poor school resources, amplifies these effects; epidemiological data from urban U.S. samples show residents in low-SES areas have 20-30% higher rates of and , attributable to greater accessibility and norms favoring use. However, protective environmental elements, such as strong ties or supervised activities, can attenuate these risks, underscoring bidirectional influences rather than deterministic causation. Developmentally, (ACEs)—encompassing abuse, neglect, and household dysfunction—exert a dose-dependent effect on later , with meta-analyses confirming that individuals with four or more ACEs face 3- to 7-fold elevated odds of illicit drug use and in adulthood compared to those with none. A of estimated 16.1% of adults report four or more ACEs, linking them to altered responses and development that impair impulse control. Early-life disrupts epigenetic regulation of reward genes, fostering hypersensitivity to substances during , when the brain's mesolimbic system undergoes maturation; prospective studies indicate that ACE-exposed youth initiate and 2-3 years earlier on average. represents a critical window, as first substance exposure before age 15 triples lifetime risk versus later onset, due to incomplete myelination and heightened in decision-making circuits. These triggers interact with genetic predispositions, but empirical models emphasize that developmental insults prime the brain for maladaptive , evident in fMRI studies showing exaggerated ventral striatal responses to drug cues among histories.

Types and Manifestations

Substance-Based Addictions

Substance-based addictions, also termed substance use disorders (SUDs), refer to chronic conditions involving compulsive use of psychoactive substances despite harmful consequences, driven by alterations in reward pathways such as the mesolimbic system. These disorders encompass a range of legal and illicit substances that induce , , and escalating consumption patterns. According to the , SUD diagnosis requires at least two of eleven criteria within a 12-month period, including using larger amounts or over longer periods than intended, persistent desire or unsuccessful efforts to reduce use, excessive time spent obtaining or recovering from the substance, cravings, failure to fulfill major role obligations, continued use despite social or interpersonal problems, reduced activities due to use, risky use situations, (needing more for effect or diminished response), symptoms, and use to relieve . Severity is classified as mild (2-3 criteria), moderate (4-5), or severe (6 or more). Major categories include , , , , , and sedatives/hypnotics. use disorder (AUD) affects approximately 27.9 million individuals aged 12 and older in the United States as of 2023, representing 9.7% of that population, with symptoms including blackouts, , and manifesting as tremors or seizures. (OUD), involving prescription painkillers, , or synthetic opioids like , impacted about 2.5 million Americans in recent estimates, characterized by rapid , severe (e.g., nausea, muscle aches, anxiety), and high overdose risk due to respiratory depression. addictions, such as to or , feature intense euphoria followed by crashes, with long-term effects including cardiovascular damage and ; these substances hijack reuptake, leading to compulsive redosing. Cannabis use disorder arises from repeated THC exposure, with criteria met by around 4 million U.S. cases annually, often involving , cognitive impairments, and irritability or . addiction, prevalent in products, affects over 28 million smokers with dependence reinforced by rapid delivery to the , causing headaches, , and increased anxiety. , , or disorders from benzodiazepines or barbiturates involve rebound anxiety upon cessation and risks of overdose when combined with or opioids. Overall, SUDs afflicted 48.5 million aged 12 or older in the U.S. in 2023, equating to 17.1% of that demographic, with illicit drugs contributing 28.9 million cases. These addictions differ from behavioral ones by directly introducing exogenous chemicals that dysregulate endogenous neurotransmitters, often yielding faster .

Behavioral Addictions

Behavioral addictions, also known as process addictions, refer to the compulsive pursuit of non-substantive rewarding activities that lead to significant impairment or distress, mirroring the core features of substance use disorders such as , symptoms, loss of control, and continued engagement despite adverse consequences. In the , disorder is the sole formally recognized behavioral addiction, classified under Substance-Related and Addictive Disorders due to shared diagnostic criteria including persistent preoccupation, unsuccessful efforts to cut down, and jeopardizing important activities. Internet gaming disorder is listed in Section III for conditions warranting further study, characterized by excessive gaming leading to clinically significant impairment over 12 months, with nine criteria analogous to those for disorder. These disorders activate the brain's reward circuitry similarly to substances, with studies demonstrating surges in the ventral during cues, akin to drug-induced responses, supporting a unified model. However, the classification remains debated, as behavioral addictions lack physiological dependence on external agents and may overlap with or disorders, prompting caution against overpathologizing normative behaviors like enthusiastic or . manifests as needing increased time or intensity in the activity for satisfaction, while can include , anxiety, or restlessness upon cessation. Common examples include compulsive shopping, or buying disorder, involving recurrent purchasing sprees resulting in financial distress, estimated to affect 5.8% of the U.S. population with higher rates among women; and hypersexual disorder, marked by intrusive sexual thoughts and risky behaviors despite harm, though not codified. Other proposed types encompass excessive exercise, workaholism, and use beyond gaming, with varying: addiction around 10-30% in general populations and higher in adolescents, often linked to from stress. Gambling disorder stands at 2-3% globally, disproportionately impacting males and those with comorbid mood disorders. These manifestations underscore the role of cue-reactivity and habit formation in perpetuating cycles, distinct from mere excess but requiring empirical thresholds for to avoid diagnostic inflation.

Development, Progression, and Epidemiology

Stages of Onset and Escalation

The onset of addictive behavior typically commences with initial experimentation, wherein an individual encounters a substance or engaging activity—such as or excessive use—that elicits acute reward through release in the , particularly the . This hedonic response, often driven by , , or alleviation, reinforces the without immediate adverse consequences, setting the foundation for repetition. Empirical data from longitudinal studies reveal that substance frequently occurs during , a developmental window characterized by elevated reward sensitivity and immature executive control in the , increasing susceptibility to progression; for instance, early onset correlates with heightened risks of escalation to other substances in twin-control analyses. Similar patterns emerge in behavioral addictions, where intermittent reinforcement, as in slot machine wins, fosters initial persistence despite variable outcomes. Escalation unfolds through neuroadaptations that transform occasional engagement into and compulsive patterns, commonly framed by a three-stage : binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation. In the initial binge/intoxication phase, repeated exposure shifts from ventral striatal pleasure-seeking to dorsal striatal automation, with developing as downregulation diminishes euphoric effects, necessitating higher doses or frequency for equivalent reward—a process observed across substances like and behaviors like pathological via brain imaging. This stage marks early , where use interferes with daily functioning, as evidenced by clinical cohorts showing dose in over 70% of transitioning users within months of regular intake. Further progression incorporates the /negative affect stage, wherein cessation triggers , anxiety, and stress via extended hyperactivity (e.g., elevated corticotropin-releasing ), compelling negative reinforcement to alleviate discomfort and perpetuating the cycle. Neurochemical evidence from models and fMRI demonstrates hypocretin and dynorphin dysregulation amplifying this drive, with studies linking it to rapid escalation in vulnerable individuals, such as those with familial substance , who exhibit faster transitions to dependence. The preoccupation/anticipation stage solidifies , impairing prefrontal and heightening cue-induced craving, as orbital frontal cortex hypoactivity correlates with compulsive in PET scans of abstinent addicts. Across addictive behaviors, this escalation trajectory—supported by >60% one-year rates post-detox—reflects cumulative circuit remodeling rather than isolated events, with behavioral parallels in disorders like internet showing analogous prefrontal deficits. In the , approximately 16.8% of individuals aged 12 or older—equating to about 48.4 million —met criteria for a in 2024, reflecting a slight decline of roughly 100,000 cases from 2023 levels. Globally, use disorder affects an estimated 4.9% of adults, with higher rates among men (7.8%) than women (1.5%), while use disorders contribute to a broader burden tracked by the , showing stable but persistent prevalence since the 1990s. Prevalence trends for substance-based addictions have shown relative stability in recent years, with U.S. National Survey on Drug Use and Health (NSDUH) data from 2021 to 2024 indicating consistent rates of past-year illicit drug use and alcohol misuse, though prescription drug misuse saw a noted uptick in short-term recall metrics. Behavioral addictions, however, exhibit upward trajectories linked to proliferation; for instance, internet gaming disorder prevalence has ranged from 0.7% to 15.6% in naturalistic populations since 1998, with meta-analyses confirming a pooled global rate of 3.3% as of recent studies. past-year rates hover at 1.41% globally among adults, with adolescent disorder at 0.89% to 1%, amid rising access to digital platforms. Demographic patterns reveal pronounced disparities. Men consistently show higher SUD prevalence across most substances, including illicit drugs and , with rates exceeding those of women until advanced ages; for gaming disorder, male prevalence reaches 8.5% versus 3.5% in females. Age gradients peak in young adulthood (18-25 years), where SUD rates are elevated due to initiation factors, declining thereafter but persisting into later life for some cohorts. Racial/ethnic variations include higher use among White adults (70.3% past-year) compared to other groups, while socioeconomic stressors like correlate with increased self-reported problems among ever-users. Behavioral addictions disproportionately affect youth and lower socioeconomic strata, with young males overrepresented in problematic and .
Demographic FactorKey Patterns in Addictive Behaviors
Males: Higher SUD (e.g., , illicit drugs) and behavioral (e.g., 8.5%, ) rates; Females: Elevated prescription misuse in some datasets.
Peaks 18-25 for SUD onset; /adolescents higher for behavioral (e.g., 0.77-57.5% at-risk). Declines post-30 but stable in seniors for .
Ethnicity/RaceWhites: Highest use (70.3%); Variations in drug SUD by group, with social stressors amplifying risks in minorities.
Lower SES/poverty linked to higher abuse identification and vulnerability via stressors.

Individual and Societal Consequences

Health and Psychological Effects

Addictive behaviors, encompassing both substance use disorders and behavioral addictions, exert severe physical health consequences, primarily through direct and chronic physiological strain. Substance use disorders are linked to a range of organ-specific damages, including as the most common , alongside hepatic from , pulmonary disorders from , and infectious diseases like and C from injection drug use. , drug overdose deaths totaled 105,007 in 2023, underscoring the acute mortality risk. Behavioral addictions, such as or excessive , contribute less directly to physical pathology but promote neglect of , , and exercise, elevating risks for , , and stress-related immunodeficiencies. Psychologically, addictive behaviors disrupt executive functioning, impulse control, and emotional regulation via alterations in and pathways, fostering cycles of , , and craving. Substance use disorders correlate with high psychiatric rates, with approximately 50% of affected individuals experiencing concurrent mental disorders, including mood disorders (26% prevalence in non-alcohol drug users) and anxiety disorders. Behavioral addictions similarly yield , transient anxiety relief followed by intensified distress, and diminished insight into harmful patterns despite awareness of consequences. Co-occurring conditions often amplify functional impairments, with substance-involved individuals showing elevated rates of , , and compared to those without addictions. Long-term effects include neurocognitive deficits, such as impaired and , persisting even in remission due to structural changes like reduced volume. These outcomes reflect causal pathways where repeated engagement overrides homeostatic mechanisms, leading to a net loss of approximately 25 disability-adjusted life years per person with severe substance use disorders. Empirical data indicate bidirectional influences, yet addictive behaviors predominantly drive progression of secondary psychopathologies through reinforced avoidance of adaptive .

Economic and Social Ramifications

Addictive behaviors exact a profound economic toll on individuals through diminished earning potential, unemployment, and treatment expenses, while societies bear costs in healthcare, criminal justice, and forgone productivity. In the United States, the aggregate annual expense of drug abuse reached approximately $820 billion as of recent estimates, factoring in criminal activities, medical care, and workplace absenteeism or losses. Substance misuse specifically accounted for $249 billion in alcohol-related impacts and $193 billion from illicit drugs in 2023 data compiled by federal health authorities. For opioids alone, illicit use imposed a $2.7 trillion burden in 2023, representing 9.7% of gross domestic product and encompassing premature mortality, healthcare utilization, and productivity deficits. Globally, substance use disorders afflicted 39.5 million individuals in 2021, yielding millions of disability-adjusted life years lost and straining public resources, though comprehensive economic valuations remain fragmented across regions. Behavioral addictions, such as pathological , amplify these fiscal strains via similar mechanisms of lost wages and financial ruin, with societal expenditures including bailouts for affected households and elevated filings. Healthcare systems absorb in attributable costs; for instance, U.S. expenses tied to substance use disorders totaled $13.2 billion annually in analyzed . Criminal justice outlays further compound the ledger, as fuels offenses ranging from to , diverting funds from productive investments. On the social front, addictive behaviors erode familial bonds and perpetuate cycles of dysfunction, with parental substance use disorders elevating risks for , physical harm, and impaired emotional regulation or impulse control. Households suffer disruptions in routines, attachments, communication, and , often culminating in , child welfare interventions, or intergenerational addiction patterns. In behavioral domains like , family members endure , financial depletion, and secondary mental health burdens such as anxiety or . Communities face amplified , , and incarceration linked to addiction-driven behaviors, including victimization or perpetration of offenses to sustain habits. These dynamics foster fragmentation, reduced trust, and heightened public safety expenditures, with drug-related arrests comprising a substantial share of caseloads. Overall, such ramifications underscore addiction's role in undermining cohesion and individual agency, independent of prevailing narratives framing it solely as a inevitability.

Treatment Approaches

Behavioral and Psychological Interventions

represents a cornerstone of behavioral interventions for addictive behaviors, targeting maladaptive thought patterns and behaviors through structured techniques such as relapse prevention and skills training. Meta-analyses of randomized controlled trials indicate that yields small to moderate reductions in substance use compared to inactive controls, with effects most pronounced in early follow-up periods (1-6 months post-treatment). For and other drug use disorders, demonstrates efficacy across various comparator conditions, including no treatment or nonspecific controls, though long-term outcomes show diminishing returns without ongoing support. In behavioral addictions like , similarly outperforms minimal interventions by fostering coping strategies, albeit with effect sizes comparable to those in substance domains. Motivational interviewing (MI), a client-centered approach emphasizing discrepancy between current behaviors and personal goals, enhances and reduces substance use in short-term follow-ups when compared to no . Systematic reviews of trials confirm MI's role in increasing motivation for change, particularly among individuals with lower dependence levels, though benefits wane beyond 6-12 months without integration into broader therapies. When combined with , MI augments outcomes by improving adherence, as evidenced in studies of and , where dual interventions outperform CBT alone in reducing craving and consumption. Contingency management (CM) employs principles, providing tangible rewards for verified or treatment compliance, and has demonstrated robust efficacy across substance use disorders over three decades of research. Randomized trials and reviews show CM significantly boosts rates and attendance, with effect sizes surpassing those of verbal therapies alone, particularly for stimulants like and . Implementation challenges, including cost and potential for non-sustaining effects post-reward cessation, limit widespread adoption, yet evidence supports its superiority in promoting behavioral change through direct . Mindfulness-based interventions (MBIs), such as mindfulness-based relapse prevention, aim to cultivate of urges and reduce automatic responses, showing preliminary in lowering craving intensity in substance and behavioral addictions. Systematic reviews of randomized trials report moderate reductions in mental and relapse risk, though high-quality evidence remains limited, with effects varying by addiction type and participant adherence. MBIs complement other therapies by addressing but do not consistently outperform established methods like in metrics. Family and couples therapies integrate relational dynamics into , addressing behaviors and improving overall functioning in substance use disorders. Meta-analyses indicate that involving members reduces consumption and enhances retention, with multidimensional therapy yielding significant improvements in adolescent outcomes compared to individual approaches. These interventions leverage as a causal factor in sustained , though depends on family willingness and absence of comorbid dysfunction. Overall, behavioral and psychological interventions collectively outperform waitlist controls but exhibit rates of 40-60% within one year, underscoring the need for , individualized application grounded in empirical validation rather than ideological assumptions.

Pharmacological and Medical Options

Pharmacological interventions for addictive behaviors primarily target substance use disorders (SUDs), where FDA-approved medications address , craving, and reinforcement mechanisms, often requiring concurrent behavioral for optimal outcomes. For , (a partial mu-opioid ), (a full mu-opioid ), and (an ) are FDA-approved and reduce illicit use by 50-70% in clinical trials, while lowering overdose mortality risk by up to 50% compared to no medication. In alcohol use disorder, (50 mg daily) decreases relapse rates by 20-30% by blocking euphoric effects, stabilizes post-acute syndrome to support abstinence, and disulfiram induces aversive reactions to via buildup, with meta-analyses confirming modest efficacy for all three when adherence is maintained. For tobacco/nicotine dependence, FDA-approved options include nicotine replacement therapies (e.g., patches delivering 21 mg/day, gums, lozenges), (a partial reducing cravings and ), and bupropion (a norepinephrine-dopamine ), which approximately double quit rates over in randomized controlled trials. Stimulant use disorders (e.g., , ) lack FDA-approved pharmacotherapies, with trials of agents like or antidepressants showing inconsistent results limited to symptom management rather than sustained abstinence. For behavioral addictions, no medications are FDA-approved specifically, and evidence derives from small trials targeting shared neurobiological pathways like or reward dysregulation; opioid antagonists such as (effective in reducing urges in some randomized studies) and show preliminary promise for disorder via network meta-analyses, though effect sizes are small and relapse common without therapy. Off-label antidepressants (e.g., SSRIs) or mood stabilizers address comorbidities like anxiety in internet or compulsive behaviors but yield mixed outcomes, with Cochrane-level reviews emphasizing insufficient high-quality data for routine use. Medical options complement through supervised protocols, which mitigate severe (e.g., benzodiazepines for reducing risk by 80%), or emerging neuromodulation techniques like , which inhibit craving circuits in pilot studies for both SUDs and behavioral addictions but remain investigational pending larger trials. Overall, success rates hover at 20-50% long-term across addictions, underscoring the need for individualized assessment and monitoring for side effects like with .

Self-Directed and Abstinence-Focused Methods

Self-directed methods for addressing addictive behaviors encompass strategies where individuals independently employ cognitive, behavioral, and motivational tools to interrupt patterns of compulsion without reliance on professional clinicians or structured therapy. These approaches often draw from cognitive-behavioral principles, emphasizing self-monitoring, goal-setting, and skill-building to enhance self-regulation and personal agency in recovery. Empirical evidence indicates that self-guided interventions, such as online programs and apps, can yield meaningful reductions in addictive behaviors, particularly when users exhibit high motivation and self-efficacy. For instance, a 2021 randomized controlled trial of a self-guided internet-based intervention for gambling disorder reported significant decreases in gambling frequency and severity among participants, with effect sizes comparable to therapist-led treatments. Similarly, self-directed technology-based methods post-discharge from formal care have shown sustained improvements in adult recovery outcomes for various addictions. Abstinence-focused self-directed methods prioritize total cessation of the addictive behavior as the primary pathway to recovery, contrasting with models that permit controlled engagement. These include mutual self-help groups adapted for behavioral addictions, such as , which follows a 12-step framework originally developed for substance use but applied to compulsive gambling since 1957, fostering and spiritual inventory to achieve and maintain . Secular alternatives like , launched in 1994, utilize evidence-based tools from and motivational enhancement to build coping skills and urge management, explicitly supporting goals while accommodating individual choice. A 2013 randomized trial evaluating a web-based application for problem drinkers demonstrated superior rates and reduced alcohol consumption compared to waitlist controls, with participants reporting enhanced . For and addictions, self-directed methods often involve protocols, app blockers, and journaling to track triggers and reinforce commitment to zero-use periods. Peer-reviewed studies highlight the role of self- in predicting long-term success, with higher baseline self-efficacy linked to reduced relapse at two-year follow-ups in substance and samples. A 2006 study of self-help group participation post-drug treatment found that continued engagement correlated with 72% rates at one-year follow-up, underscoring the value of ongoing self-directed peer reinforcement. Systematic reviews of affirm its efficacy across addictive behaviors, including behavioral ones, with process evaluations showing improvements in motivation and behavioral change techniques that sustain . While individual variability exists, meta-analyses indicate that -oriented outperforms non- approaches in achieving durable recovery for severe cases, though success hinges on consistent application and addressing underlying vulnerabilities like .

Controversies and Debates

Disease Model Versus Choice and Agency

The disease model of posits that addictive behaviors from a , relapsing alteration in circuitry, particularly involving the reward pathway and prefrontal cortex, rendering individuals with diminished capacity for akin to other neurological disorders. Proponents, including the , cite evidence of dysregulation and structural changes in regions like the , alongside estimates from twin studies ranging from 40% to 60% for substance use disorders, as indicating a primarily biomedical beyond voluntary . This framework, formalized in definitions by the American Society of Addiction Medicine since 2011, frames as a primary requiring lifelong medical management, with rates often exceeding 40-60% in treated populations, underscoring its progressive and intractable nature. In contrast, the and agency model, advanced by researchers such as Gene Heyman and , conceptualizes as a volitional, goal-directed learned through , where individuals retain capacity even amid heavy use, influenced by costs, benefits, and environmental contingencies rather than an irreversible brain pathology. Heyman argues in his 2009 analysis that empirical data, including controlled experiments, demonstrate addicts weigh alternatives and modulate intake based on incentives, contradicting claims of ; for instance, drops sharply when prices rise or legal risks increase, patterns inconsistent with a loss-of-control . Peele extends this via the life-process approach, emphasizing as a maladaptive response to life stressors, recoverable through personal resolve without medical intervention, and critiques the model for conflating correlation (brain changes) with causation while ignoring that such alterations resemble those from habitual learning and reverse with abstinence. Empirical support for the choice perspective includes high rates of natural recovery, with studies estimating that 75% of individuals with eventually remit, and 25-40% or more achieving this without formal or groups, often through self-motivated shifts rather than pharmacological aids. Longitudinal data further reveal that brain alterations in addiction, such as reduced gray matter in the , are partially reversible within months to years of sustained , as evidenced by functional MRI studies showing normalization of reward processing and executive function, unlike the permanent deficits in canonical brain diseases. Heritability, while notable—e.g., 51% for use disorder in meta-analyses of twin data—leaves substantial variance attributable to non-genetic factors like and environment, with monozygotic twin discordance rates indicating no deterministic genetic override. The debate highlights tensions in and : the disease model, dominant in academic and federal institutions despite critiques of overpathologizing transient behaviors, may incentivize dependency on interventions with modest efficacy (e.g., medication-assisted retention below 50% long-term), potentially amplified by institutional biases favoring biomedical funding over behavioral accountability. Conversely, emphasizing aligns with on self-change, promoting strategies that leverage incentives and , though it risks underestimating vulnerabilities in subsets with comorbid psychiatric conditions; resolution favors hybrid views recognizing probabilistic brain influences but prioritizing evidence of retained volition, as voluntary cessation exceeds treated outcomes in population surveys.

Harm Reduction Policies Versus Strict Abstinence

Harm reduction policies prioritize minimizing immediate risks associated with addictive behaviors, such as substance use, through measures like syringe services programs (), distribution, and opioid substitution therapies (e.g., ), without mandating . These approaches have demonstrated reductions in and hepatitis C transmission among people who inject drugs, with SSPs linked to decreases in HIV incidence by up to 18% in affected communities. Similarly, expanded access has prevented over 1,650 overdose deaths in alone between 2019 and 2023, reflecting broader patterns in U.S. initiatives. However, some analyses indicate potential trade-offs, including elevated opioid-related mortality in areas with new SSP implementations, suggesting that while infectious disease harms decline, overall substance-related deaths may not uniformly decrease. In contrast, strict abstinence policies emphasize complete cessation of addictive substances, often enforced through , mandatory , and abstinence-based programs like or residential therapeutic communities. Sweden's zero-tolerance framework, formalized in 1988, has correlated with Europe's lowest rates of illicit drug use among adults (around 5-7% lifetime ) and adolescents, achieved via heavy investment in enforcement, prevention, and abstinence-oriented interventions. Abstinence-focused s yield variable success, with inpatient programs reporting 49% completion rates and 36% achieving at discharge, though long-term remission (six months or more) occurs in 35-54% of cases post-. Critics of non-medication approaches for opioids argue they may exacerbate harms compared to no treatment, with higher and overdose risks due to reduced . Comparative policy outcomes highlight divergent priorities: Portugal's 2001 decriminalization, incorporating harm reduction elements like dissuasion commissions and treatment referrals, reduced drug-induced deaths from 80 per million in 2001 to 23 per million by 2019 and curbed HIV infections among injectors from 1,400 new cases in 2003 to under 100 annually by 2018. Yet Portugal exhibits higher problematic drug use rates than Sweden, where strict policies maintain lower overall consumption but face accusations of elevating harms through stigma and limited access to alternatives. Meta-analyses of interventions for vulnerable populations, such as the homeless, find minimal differences in substance use reduction between harm reduction and abstinence strategies versus standard care, with effect sizes around -0.47 standard deviations for contingency management techniques adaptable to either paradigm. The debate persists due to mismatched metrics: excels in acute risk mitigation but shows weaker links to sustained or , potentially prolonging by normalizing use. policies foster lower societal through deterrence but suffer high (e.g., only 24% one-year for short-stay treatments) and may deter help-seeking. Mainstream literature, often institutionally biased toward , underemphasizes long-term societal costs like sustained rates, while advocates prioritize causal and permanent resolution over interim palliation. Empirical favors models, yet choice hinges on valuing immediate harm aversion against enduring behavioral change.

Prevention and Mitigation Strategies

Individual-Level Prevention

Individual-level prevention of addictive behaviors emphasizes personal in cultivating and mitigating risks through self-directed actions, such as skill development and habit formation, which empirical studies show can reduce and progression to dependence. identifies key modifiable individual factors, including attitudes toward substance use, , and coping mechanisms, as central to averting addictive patterns. For instance, programs targeting skills and normative beliefs about peer usage have demonstrated reductions in adolescent substance by up to 25% in randomized trials. These strategies operate on causal mechanisms like reinforcing realistic expectations about short-term rewards versus long-term harms, countering the pleasure-seeking impulses that drive early experimentation. Developing self-regulation and refusal skills forms a core component, with meta-analyses indicating that interventions enhancing impulse control and lower vulnerability to behavioral addictions, such as excessive or , by strengthening prefrontal cortex-mediated inhibition. Individuals can proactively build via practices like mindfulness training or , which studies link to decreased craving susceptibility; for example, a 2020 found such techniques reduced risk in at-risk populations by fostering awareness of triggers. Protective traits like and intrinsic motivation further buffer against onset, as evidenced by longitudinal data showing optimistic adolescents 15-20% less likely to engage in . Avoiding early exposure—delaying first use beyond age 18—cuts addiction odds by half or more, per evidence of preserved . Lifestyle choices underpin sustained prevention, with regular and adequate correlating to 30-40% lower incidence of addictive disorders through regulation and reduced negative affect. Personal monitoring of high-risk situations, such as limiting access to addictive stimuli or selecting non-using circles, leverages to disrupt causal chains; studies confirm that individuals practicing these report fewer escalations to dependence. and spiritual practices also emerge as empirically supported buffers, with meta-analytic evidence associating them with halved odds of via enhanced purpose and moral frameworks. While genetic predispositions influence susceptibility, individual interventions prove effective across risk strata by prioritizing volitional behaviors over deterministic views.

Societal and Policy Interventions

Societal interventions for addictive behaviors encompass public campaigns, community-based programs, and regulatory measures aimed at reducing and . from school- and community-level programs indicates that structured prevention efforts, such as those targeting influences and skill-building, can delay substance use onset among by up to 20-30% in randomized trials, though long-term effects vary by fidelity. These initiatives often integrate with policy frameworks, like Finland's national action plan on , , drugs, and , which coordinates multi-level prevention under statutory mandates since 2018, correlating with stabilized or declining youth gambling participation rates. Fiscal policies, particularly excise taxation on addictive substances, demonstrate consistent efficacy in curbing consumption through price elasticity. For tobacco, a 10% tax-induced price hike typically yields a 4-5% drop in demand, contributing to global declines; in the U.S., such measures alongside smoke-free laws reduced adult smoking prevalence from 20.9% in 2005 to 11.5% in 2021. Similar patterns hold for alcohol, where higher taxes reduce heavy episodic drinking by 5-10% per 10% price increase, with evidence from systematic reviews spanning multiple countries. For sugar-sweetened beverages linked to compulsive overconsumption, taxation in places like Mexico (10% levy in 2014) cut purchases by 10% initially, though substitution effects and regressivity warrant scrutiny. These outcomes stem from addictive goods' sensitivity to cost, where higher prices disproportionately deter casual or youth users without fully eliminating entrenched addiction. Regulatory interventions focus on restricting availability and marketing to mitigate exposure. Tobacco advertising bans and packaging warnings, as in the WHO Framework Convention on Tobacco Control ratified by 182 countries since 2005, have halved advertising reach in adherent nations, aiding prevalence drops. For and , point-of-sale restrictions and age verification reduce underage access; in gambling, mandatory loss limits and registries in jurisdictions like the (introduced 2009) correlate with 10-15% harm reductions per expert consensus models. Online gambling regulations, including and spending caps, address rapid-form products' risks, with evidence from Sweden's 2019 reforms showing moderated play intensity. Legal policy shifts, such as drug , yield mixed results on mitigation. Portugal's 2001 model, redirecting resources to , stabilized overall drug use rates and cut infections by 95% among injectors by 2012, but opioid-related deaths rose post-2010 amid influx. In , 2020 decriminalization paired with expanded saw no use rate surge per surveys, yet overdose deaths climbed 25% by 2022, prompting partial recriminalization in 2024 due to unmet service capacity. Canada's 2023 exemptions similarly correlated with 5% higher toxicity deaths, underscoring that decriminalization reduces and arrests but requires robust scaling to curb harms, as isolated shifts fail to address supply potency or demand drivers. Strict enforcement, conversely, elevates black-market risks without proportionally denting use, per economic analyses. Integration of policies proves most effective, as standalone measures overlook of —where cues and availability amplify relapse. Comprehensive strategies, blending taxes, bans, and cessation support, averted 8 million U.S. premature deaths from 1964-2012. Challenges persist in evaluating behavioral addictions like , where industry mirrors tactics, delaying reforms despite evidence favoring pre-commitment tools over voluntary self-regulation. Policy success hinges on empirical monitoring, avoiding overreliance on ideological models favoring either unrestricted markets or punitive excess.

References

  1. [1]
    Neurobiology of Addiction - StatPearls - NCBI Bookshelf
    Nov 2, 2023 · A result of increased substance use to avoid withdrawal symptoms is a shift from impulsive to compulsive behavior. Compulsive behavior marks the ...
  2. [2]
    The neurobiology of addiction - PMC - PubMed Central - NIH
    Advances in neuroscience and addiction research have helped to describe the neurobiological changes that occur when a person transitions from recreational ...
  3. [3]
    Drugs, Brains, and Behavior: The Science of Addiction - NIDA - NIH
    Jul 6, 2020 · Large surges of dopamine “teach” the brain to seek drugs at the expense of other, healthier goals and activities. Cues in a person's daily ...Drug Misuse and Addiction · Health · Treatment and Recovery · References
  4. [4]
    Dopamine, behavior, and addiction | Journal of Biomedical Science
    Dec 2, 2021 · Addictive drugs are habit-forming. Addiction is a learned behavior; repeated exposure to addictive drugs can stamp in learning.
  5. [5]
    Neuroscience of Addiction: Relevance to Prevention and Treatment
    Apr 25, 2018 · Addiction, the most severe form of substance use disorder, is a chronic brain disorder molded by strong biosocial factors that has devastating consequences.
  6. [6]
    Dopamine Circuit Mechanisms of Addiction-Like Behaviors - Frontiers
    Addiction is characterized by a transition from recreational drug use to compulsive, disordered use, punctuated by cycles of abstinence, withdrawal, craving, ...
  7. [7]
    Review article The Interaction of Person-Affect-Cognition-Execution ...
    Highlights. • Addictive behaviors are linked to cue-reactivity and craving. Addictive behaviors are associated with diminished inhibitory control. Habitual ...
  8. [8]
    Neurobiological Theories of Addiction: A Comprehensive Review
    Jan 23, 2024 · They all share a similar definition of addiction as a chronic disease characterized by a loss of control over substance consumption, with the ...
  9. [9]
    Addictive behaviors: decades of research, but still so many questions!
    Oct 18, 2024 · Addictive behaviors related or not to a substance present a strong common neurobiological link (Grant et al., 2006), but also some specific ...Missing: characteristics | Show results with:characteristics
  10. [10]
    Introduction to Behavioral Addictions - PMC - NIH
    The essential feature of behavioral addictions is the failure to resist an impulse, drive, or temptation to perform an act that is harmful to the person or to ...
  11. [11]
    Addictive behaviour - World Health Organization (WHO)
    Disorders due to addictive behaviours are recognizable and clinically significant syndromes associated with distress or interference with personal functions ...
  12. [12]
    A 'components' model of addiction within a biopsychosocial framework
    Jul 12, 2009 · This paper argues that all addictions consist of a number of distinct common components (salience, mood modification, tolerance, withdrawal, conflict and ...
  13. [13]
    Component Model of Addiction Treatment - PubMed Central - NIH
    According to this model, all addictive behaviors consists of six core components: (i) salience, which refers to the addictive behavior becoming the most ...
  14. [14]
    Habit, choice, and addiction - PMC - NIH
    Nov 9, 2020 · Addiction was suggested to emerge from the progressive dominance of habits over goal-directed behaviors.
  15. [15]
    Drug Misuse and Addiction | National Institute on Drug Abuse - NIDA
    Jul 6, 2020 · Addiction is defined as a chronic, relapsing disorder characterized by compulsive drug seeking and use despite adverse consequences.<|separator|>
  16. [16]
    Defining Compulsive Behavior - PMC - PubMed Central - NIH
    Apr 23, 2019 · In addiction, behavior typically becomes more compulsive in later stages of the disorder, while compulsive behaviors characterize OCD from early ...
  17. [17]
    Does compulsion explain addiction? - PMC - PubMed Central - NIH
    Apr 8, 2024 · Compulsion is often regarded as a key feature of addictions and obsessive‐compulsive disorders (OCD). ... In other words, habits and the ventral ...
  18. [18]
    The transition to compulsion in addiction - PMC - PubMed Central
    Compulsion is a cardinal symptom of drug addiction (severe substance use disorder). However, compulsion is observed in only a small proportion of individuals.
  19. [19]
    On habits and addiction: An associative analysis of compulsive drug ...
    The aim of the current paper is to develop a theoretical context for thinking about the role of habit learning in the addiction process.
  20. [20]
    The Neuroscience of Drug Reward and Addiction - PMC
    Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85 ...
  21. [21]
    Neurobiologic Processes in Drug Reward and Addiction - PMC
    The mesolimbic pathway, in particular, was identified as the key component in reward assessment. This pathway originates with dopaminergic cell bodies in the ...
  22. [22]
    Addiction: Beyond dopamine reward circuitry - PNAS
    These findings show that addiction affects not only the DA reward circuit but circuits involved with conditioning/habits, motivation, and executive functions.
  23. [23]
    Dopamine and Addiction - PubMed - NIH
    Jan 4, 2020 · As a result of habitual intake of addictive drugs, dopamine receptors expressed in the brain are decreased, thereby reducing interest in ...
  24. [24]
    Dopamine in Drug Abuse and Addiction: Results of Imaging Studies ...
    These brain-imaging studies suggest 2 abnormalities in addicted subjects that would result in decreased output of DA circuits related to reward; that is, ...
  25. [25]
    Neurobiology of addiction: a neurocircuitry analysis - PubMed Central
    Anti-reward circuits are engaged as neuroadaptations during the development of addiction, producing aversive or stress-like states. These aversive states are ...
  26. [26]
    The addicted human brain: insights from imaging studies - PMC - NIH
    Imaging studies have revealed neurochemical and functional changes in the brains of drug-addicted subjects that provide new insights into the mechanisms ...
  27. [27]
    Implications of neuroimaging findings in addiction - PMC
    Addiction leads to structural and functional brain changes implicated in reward, memory, motivation, and control (Volkow et al., 2019; Lüscher et al., 2020).
  28. [28]
  29. [29]
    Introduction: Addiction and Brain Reward and Anti-Reward Pathways
    Addiction appears to correlate with a hypo-dopaminergic dysfunctional state within the reward circuitry of the brain. Neuroimaging studies in humans add ...
  30. [30]
  31. [31]
    The heritability of alcohol use disorders: a meta-analysis of twin and ...
    We performed a meta-analysis of twin and adoption studies and explored the impact of sex, assessment method (interview v. hospital/population records), and ...
  32. [32]
    The Genetic Basis of Addictive Disorders - PMC - PubMed Central
    Evidence from family, adoption, and twin studies converges on the relevance of genetic factors in the development of addictions including SUDs and gambling.
  33. [33]
    Evidence for the DRD2 Gene as a Determinant of Reward ...
    Other studies from Yale University showed that a haplotype block of the DRD2 gene A1 allele was associated with AUD and heroin dependence. GWAS studies of ...
  34. [34]
    Initial Study on COMT and DRD2 Gene Polymorphisms as Well as ...
    Dec 15, 2021 · The DRD2 receptor gene polymorphisms are related with the intensity of alcohol craving. It seems that the character traits like “self-targeting” ...
  35. [35]
    The genetic landscape of substance use disorders - Nature
    May 29, 2024 · Alcohol use disorder​​ These risk variants mapped to 66 genes, including previously implicated DRD2 (Dopamine Receptor D2), along with additional ...Missing: COMT | Show results with:COMT
  36. [36]
    THE NEUROBIOLOGY OF SUBSTANCE USE, MISUSE, AND ... - NCBI
    Compulsive substance seeking is a key characteristic of addiction, as is the loss of control over use. Compulsivity helps to explain why many people with ...
  37. [37]
    The Brain on Drugs: From Reward to Addiction - ScienceDirect.com
    Aug 13, 2015 · Repeated drug administration triggers neuroplastic changes in glutamatergic inputs to the striatum and midbrain dopamine neurons, enhancing the ...
  38. [38]
    Addiction and the brain: the role of neurotransmitters in the cause ...
    Drugs of abuse are able to exert influence over the brain reward pathway either by directly influencing the action of dopamine within the system, or by altering ...
  39. [39]
    The genetics of addiction—a translational perspective - Nature
    Jul 17, 2012 · This selective review outlines and highlights the need for a multi-method translational approach to genetic studies of these important conditions.
  40. [40]
    Genomic factors associated with substance use disorder relapse
    Specific gene polymorphisms like DRD2, GABRA, COMT, and DAT may relate to SUD relapse. •. Epigenetics play a role in SUD, such as CpG hypermethylation. •. HTR2A ...
  41. [41]
    Generalized genetic liability to substance use disorders - JCI
    Jun 3, 2024 · Collectively, these foundational twin studies have established that the heritability of SUDs generally ranges between 30% and 80%, with a ...
  42. [42]
    The genetic basis of addictive disorders - PubMed - NIH
    Twin studies have shown that the heritability of addictions ranges from 0.39 (hallucinogens) to 0.72 (cocaine). Twin studies indicate that genes influence ...Missing: GWAS | Show results with:GWAS
  43. [43]
    New NIH study reveals shared genetic markers underlying ...
    Mar 22, 2023 · Scientists have identified genes commonly inherited across addiction disorders, regardless of the substance being used.
  44. [44]
    Genes and Addiction - Learn Genetics Utah
    The A1 form (allele) of the dopamine receptor gene DRD2 is more common in people addicted to alcohol, cocaine, and opioids. The variation likely affects how ...
  45. [45]
    OU College of Medicine Researcher Discovers Gene Mutation That ...
    Aug 16, 2019 · COMT is the name of a gene that helps the body manage dopamine, a chemical that is released when a person drinks alcohol or takes a drug like ...Missing: DRD2 | Show results with:DRD2
  46. [46]
    Association between DRD2, 5-HTTLPR, and ALDH2 genes and ...
    Alcohol and opiate patients have common genetic variants in DRD2 and 5-HTTLPR. •. ALDH2 gene had specific effect for risk of heroin and alcohol dependence. •.
  47. [47]
    Genetic Polymorphisms on OPRM1, DRD2, DRD4, and COMT in ...
    Two single nucleotide polymorphisms (SNP) associated with dopamine receptors DRD2 (Taq1A) and DRD4 (521CT) have been studied in relation to addictive behaviors.
  48. [48]
    Addictions and Personality Traits: Impulsivity and Related Constructs
    We review recent findings that show links over developmental epochs between addictive behaviors and impulsivity, sensation-seeking, and other constructs that ...
  49. [49]
    Impulsivity as a vulnerability marker for substance-use disorders
    We will review the evidence that impulsivity is associated with addiction vulnerability by considering three lines of evidence.
  50. [50]
    The neurobiology of impulsivity and substance use disorders - NIH
    Sep 1, 2020 · Impulsivity is strongly associated with substance use disorders (SUDs). Our review discusses impulsivity as an underlying vulnerability ...
  51. [51]
    Addictions and Personality Traits: Impulsivity and Related Constructs
    Jan 4, 2014 · We review recent findings that show links over developmental epochs between addictive behaviors and impulsivity, sensation-seeking, and other constructs that ...
  52. [52]
    Individual differences in drug abuse vulnerability: d-Amphetamine ...
    High impulsive sensation seekers reported greater increases on several subjective report measures associated with drug abuse potential, including visual analog ...
  53. [53]
    Relationship Between Impulsivity, Sensation-Seeking, and Drug ...
    Oct 29, 2020 · The purpose of this study was to analyze the relationship between impulsivity, sensation-seeking, and drug use in aggressors and victims of violence.
  54. [54]
    Big 5 Personality Traits and Alcohol, Nicotine, Cannabis, and ... - NIH
    The personality profile of high neuroticism, low agreeableness, and low conscientiousness was associated with all four addictive disorders. All but one of the ...
  55. [55]
    Big Five Personality Traits and Illicit Drug Use - NIH
    High neuroticism, low agreeableness, and low conscientiousness are consistent correlates of drug use, though such patterns may be due to common familial ...
  56. [56]
    Big Five personality traits predict illegal drug use in young people
    The results found that Neuroticism, Openness, and Extraversion are positively related to ever illegal drug use whereas Agreeableness and Conscientiousness are ...
  57. [57]
    Meta-analysis of associations between five-factor personality traits ...
    May 4, 2024 · This analysis is in line with research findings showing that high conscientiousness is associated with lower levels of other problematic ...
  58. [58]
    Personality Traits and Impulsivity Tasks Among Substance Use ...
    Sep 7, 2020 · The aim of the present study is to analyze the associations between personality traits and performance on impulsivity tasks.
  59. [59]
    Study addiction and 'dark' personality traits: a cross-sectional survey ...
    Jan 26, 2021 · The preliminary results suggest that individuals' personality explains a modest proportion of their proneness to engaging in addictive studying ...
  60. [60]
    (PDF) Opinion The Myth of 'Addictive Personality' - ResearchGate
    Aug 6, 2025 · ... associated with addictive behaviors, with several important implications. Although personality traits are generally stable and enduring ...
  61. [61]
    Meta-Analysis of Individual and Environmental Factors that Influence ...
    After data collection, results showed that the effect size of environmental factors in people's tendency to addiction was 0.61 (P ≤ 0.00001), and the effect ...
  62. [62]
    Chronic Stress, Drug Use, and Vulnerability to Addiction - PMC
    Stress is a well-known risk factor in the development of addiction and in addiction relapse vulnerability. A series of population-based and epidemiological ...
  63. [63]
    Socioeconomic Status and Substance Use Among Young Adults - NIH
    This study examined the associations of three indicators of family SES during childhood—income, wealth, and parental education—with smoking, alcohol use, and ...
  64. [64]
    A meta-analysis study on peer influence and adolescent substance ...
    Jul 18, 2023 · This study consists of a systematic review and meta-analysis, with the main aim of quantifying the effect of peer influence on adolescent substance use.
  65. [65]
    Risk and protective factors of drug abuse among adolescents
    Nov 13, 2021 · Some of the risk factors are the presence of early mental and behavioral health problems, peer pressure, poorly equipped schools, poverty, poor ...
  66. [66]
    Social vulnerabilities for substance use: Stressors, socially toxic ...
    May 1, 2021 · We propose that socially based stressors play a critical role in creating vulnerability to substance use and SUDs, and as such, deserve greater empirical ...
  67. [67]
    Associations between adverse childhood experiences ... - PubMed
    Sep 7, 2023 · Conclusions: ACEs confer risk for substance use and trauma-informed approaches to substance use treatment should be considered. Study ...
  68. [68]
    Adverse childhood experiences: a meta‐analysis of prevalence and ...
    Sep 15, 2023 · The prevalence of ACEs was 39.9% for no ACE, 22.4% for one ACE, 13.0% for two ACEs, 8.7% for three ACEs, and 16.1% for four or more ACEs.
  69. [69]
    Understanding Addiction as a Developmental Disorder
    We consider the case for drug addiction as a developmental disorder, outlining the need to consider the role of genetic, epigenetic, and neurobiological ...
  70. [70]
    Sensitive periods of substance abuse: Early risk for the transition to ...
    Once a habit is established, environmental cues associated with the behavior serve as triggers for the behavior. Augmented salience of environmental cues during ...
  71. [71]
    Substance Use Disorders - Impact of the DSM-IV to ... - NCBI - NIH
    The DSM-IV substance abuse diagnosis required the endorsement of one or more symptoms (out of four, at any time) and no history of substance dependence for that ...
  72. [72]
    [PDF] DSM-5 Substance Use Disorder Assessment - NAADAC
    DSM-5 Substance Use Disorder Assessment. A. A pattern of substance use leading to clinically significant impairment or distress as manifested by at least 2 ...
  73. [73]
    Alcohol Use Disorder (AUD) in the United States: Age Groups and ...
    According to the 2024 National Survey on Drug Use and Health (NSDUH), 27.9 million people ages 12 and older (9.7% in this age group) had AUD in the past year.
  74. [74]
    Opioids | National Institute on Drug Abuse - NIDA
    Nov 22, 2024 · What is opioid use disorder? · Consuming the drug in larger amounts or for longer than intended. · Persistently wanting to cut down or regulate ...Opioid Research Findings... · Heroin · The NIH HEAL Initiative
  75. [75]
    Drugs A to Z | National Institute on Drug Abuse - NIDA
    Apr 10, 2025 · People who use benzodiazepines may develop a substance use disorder. This type of use disorder is called a sedative, hypnotic, or anxiolytic ...
  76. [76]
    What Is a Substance Use Disorder? - Psychiatry.org
    People can develop an addiction to: Alcohol; Cannabis; PCP, LSD and other hallucinogens; Inhalants, such as, paint thinners and glue; Opioid pain killers, such ...
  77. [77]
    Treatment and Recovery | National Institute on Drug Abuse - NIDA
    Jul 6, 2020 · Common medications used to treat drug addiction and withdrawal ; Opioid. Methadone; Buprenorphine ; Nicotine. Nicotine replacement therapies ( ...
  78. [78]
    [PDF] Highlights for the 2023 National Survey on Drug Use and Health
    Substance Use Disorders​​ In 2023, 48.5 million people aged 12 or older (or 17.1%) had a substance use disorder (SUD) in the past year, including 28.9 million ...
  79. [79]
    Non-substance addictive behaviors in the context of DSM-5 - NIH
    However, in DSM-5 (American Psychiatric Association, 2013), the category of “Substance-related and Addictive Disorders” replaces the “Substance-related ...
  80. [80]
    Internet Gaming - Psychiatry.org
    Gambling disorder is the only behavioral addiction (as opposed to chemical substance use disorders) identified in DSM-5-TR.
  81. [81]
    Behavioral Addictions as Mental Disorders: To Be or Not To Be?
    This article outlines pros and cons of considering “behavioral addictions” as mental disorders and the DSM-5 decision making processes.
  82. [82]
    What Is Process Addiction & Types of Addictive Behaviors?
    Jun 24, 2024 · A behavioral addiction is defined as a compulsion to continually engage in behaviors despite the negative impact on one's life.
  83. [83]
    Substance Use Disorders and Behavioral Addictions with Special ...
    Feb 26, 2025 · Another recent meta-analysis 4 estimated prevalence rates of behavioral addictions around: 10.6% for internet addiction,; 30.7% for ...
  84. [84]
    Behavioral Addictions - Amen Clinics
    Gambling Addiction: Approximately 2-3% of Americans have a gambling problem. · Shopping: An estimated 6% of women and 5.5% of men struggle with overspending.
  85. [85]
    Escalation of Drug Use in Early-Onset Cannabis Users vs Co-twin ...
    Jan 22, 2003 · A major focus of concern is the extent to which early cannabis use may increase the risks for escalation to other drug use and drug dependence.
  86. [86]
    Modeling escalation of drug intake to identify molecular targets for ...
    Escalation of drug intake is a hallmark sign of substance use disorder (SUD). Clinical studies have shown that escalation occurs across drug types.
  87. [87]
    SAMHSA releases new 2024 data on rates of mental illness and ...
    Aug 13, 2025 · 16.8 percent of the U.S. population aged 12 or older (about 48.4 million individuals) met the criteria for a substance use disorder (SUD). This ...
  88. [88]
    How Many People in the U.S. Had a Substance Use Disorder (SUD ...
    Sep 30, 2025 · Summary: 48.4 million people in the U.S. had a substance use disorder (SUD) in 2024. That's a decrease of 100,000 people from 2023, which is ...<|separator|>
  89. [89]
    Global statistics on addictive behaviours: 2014 status report - PubMed
    Results: An estimated 4.9% of the world's adult population (240 million people) suffer from alcohol use disorder (7.8% of men and 1.5% of women), with alcohol ...
  90. [90]
    Share of population with drug use disorders - Our World in Data
    The Global Burden of Disease (GBD) study provides a comprehensive assessment of global health trends. This dataset contains the prevalence and incidence ...
  91. [91]
    [PDF] Key Substance Use and Mental Health Indicators in the United States
    the 2024 NSDUH questionnaire indicated a higher prevalence of the past year misuse of prescription drugs but a lower prevalence of lifetime misuse compared ...
  92. [92]
    Internet Gaming Disorder: Trends in Prevalence 1998–2016 - PMC
    Overall prevalence of IGD ranged from 0.7–15.6% in studies of naturalistic populations (not enriched for clinical or online communities) (Figure 2). For studies ...
  93. [93]
    Prevalence of gaming disorder: A meta-analysis - ScienceDirect
    The overall pooled prevalence of GD was 3.3% (95% confidence interval: 2.6–4.0) (8.5% in males and 3.5% in females).
  94. [94]
    The prevalence of gambling and problematic gambling: a systematic ...
    Globally, 46.2% of adults and 17.9% of adolescents gambled in the past 12 months. Among adults, 8.7% engaged in any risk gambling, and 1.41% in problematic  ...
  95. [95]
    Problematic online gambling among adolescents: A systematic ... - NIH
    Between 0.77% and 57.5% of adolescents show some degree of problematic online gambling, and 0.89% to 1% show an online gambling disorder.
  96. [96]
    Age trends in rates of substance use disorders across ages 18–90
    Estimated SUD prevalences were generally higher for men compared to women at most ages until the 70s. However, disparities by race/ethnicity varied with age.
  97. [97]
    Alcohol and Drug Abuse Statistics (Facts About Addiction)
    Mar 26, 2025 · Rates of substance use, addiction, and related issues vary by age, gender, ethnicity, and other demographic classifications. Adolescents ...
  98. [98]
    [PDF] Racial/Ethnic Differences in Substance Use, Substance ... - SAMHSA
    The estimate of past year alcohol use among people aged. 12 or older was highest for White people (70.3 percent) compared with the estimates for people in ...
  99. [99]
    Socioeconomic Disparities and Self-reported Substance Abuse ...
    Lower income individuals are more likely to report substance abuse problems, suggesting poverty is associated with self-identification of these issues.
  100. [100]
    Gambling Prevalence & Demographics (2025) - Addiction Help
    Oct 19, 2025 · About 5 million Americans have compulsive gambling, with men more likely than women. Young men/boys are more likely to have problematic  ...
  101. [101]
    Whos Most Vulnerable to Substance Use & Addiction?
    Nov 2, 2024 · Understanding who is most at risk for substance use and addiction involves examining specific demographic factors such as gender, race, ...Risk Factors By Demographics · Age And Education Impact · Ethnic Disparities<|separator|>
  102. [102]
    Physical health status of people with substance use disorders
    Sep 9, 2025 · The most common physical illness among people with substance use disorders is cardiovascular disease. Significant gender-based differences were ...
  103. [103]
    Systematic review of guidelines for managing physical health during ...
    Jun 28, 2022 · Substance use disorders are associated with significant physical health comorbidities, necessitating an integrated treatment response.
  104. [104]
    Drug Overdose Deaths in the United States, 2003–2023 - CDC
    Dec 19, 2024 · The number of drug overdose deaths in 2023 was 105,007. Age-adjusted death rates were calculated using the direct method and the 2000 U.S. ...
  105. [105]
    Health Risks of Substance Abuse - American Addiction Centers
    Substance use is associated with various neurological and behavioral conditions, ranging from headaches and changes in mood and perception to seizures and ...
  106. [106]
    [PDF] Comorbidities in drug use disorders** - UNODC
    Mar 9, 2022 · Data from many countries and cultures indicated a high prevalence of psychiatric comorbidity among people with drug use disorders, with about 50 ...
  107. [107]
    Co-Occurring Disorders in Substance Abuse Treatment - NIH
    Among individuals with drug use disorder (other than alcohol), rates of co-occurring mood disorders were found to be 26%; rates of anxiety disorders were found ...
  108. [108]
    A systematic review on Substance Addiction: medical diagnosis or ...
    Patients with substance use disorders are able to acknowledge the potential negative consequences of following the addictive behaviour, admitting that the ...
  109. [109]
    The prevalence of comorbid serious mental illnesses and substance ...
    People in prison with substance use disorders had significantly higher odds of comorbid non-affective psychosis or major depression. Around one in two people in ...
  110. [110]
    Recovery housing for substance use disorder: a systematic review
    Mar 5, 2025 · In addition to high mortality rates, SUD is associated with a loss of approximately 25 disability-adjusted life years per affected person (4).
  111. [111]
    Drug use and mental health: Comorbidity between substance use ...
    Mood, anxiety, and psychotic disorders commonly occur with alcohol and substance use disorders; such comorbidity is often associated with higher disease ...Missing: data | Show results with:data
  112. [112]
    NCDAS: Substance Abuse and Addiction Statistics [2025]
    In 2023, 20.4 million or 7.9% of all adults aged 18 and older in the US had both AMI and at least one SUD in the past year. 6.8 million, or 2.6% of all adults ...
  113. [113]
    Addiction and Substance Misuse Reports and Publications | HHS.gov
    Aug 31, 2023 · The misuse of and addiction to opioids—including prescription pain relievers, heroin, and synthetic opioids such as fentanyl—have become common ...Missing: based | Show results with:based
  114. [114]
    The Staggering Cost of the Illicit Opioid Epidemic in the United States
    Mar 26, 2025 · In 2023 alone, illicit opioids, primarily fentanyl, cost Americans an estimated $2.7 trillion (in December 2024 dollars), equivalent to 9.7 percent of GDP.
  115. [115]
    [PDF] World Drug Report 2023 - UNODC
    Eastern Europe (1.3 per cent of the adult population) and North America (1.0 per cent) remain the two subregions with the highest estimated prevalence of ...
  116. [116]
    Assessment of Annual Cost of Substance Use Disorder in US ... - NIH
    Mar 5, 2021 · Total annual estimated attributable SUD medical cost in hospitals was $13.2 billion. By substance type, the cost ranged from $4 million for ...
  117. [117]
    Family and social aspects of substance use disorders and treatment
    Children of parents with SUDs are at increased risk for abuse or neglect, physical problems, poor behavioral or impulse control, poor emotional regulation, ...
  118. [118]
    The Impact of Substance Use Disorders on Families and Children
    The negative impacts of parental SUDs on the family include disruption of attachment, rituals, roles, routines, communication, social life, and finances.
  119. [119]
    Societal and Family Impact of Gambling Addiction - Immunize Nevada
    Nov 27, 2024 · Long-term exposure to these conditions can lead to the development of mental health issues in family members, including depression, anxiety, and ...
  120. [120]
    Family and social aspects of substance use disorders and treatment
    Other social problems associated with SUDs include housing instability, homelessness, criminal behaviors (as a victim or as a perpetrator) and incarceration, ...
  121. [121]
    Economic impact of addiction | Research Starters - EBSCO
    Moreover, addiction often leads to heightened criminal activity, with a substantial portion of arrests related to drug offenses.
  122. [122]
    An Evaluation of Cognitive Behavioral Therapy for Substance Use ...
    CBT produced small to moderate effects on substance use when compared to inactive treatment and was most effective at early follow-up (1–6 months post-treatment) ...
  123. [123]
    Efficacy of Cognitive Behavioral Therapy for Alcohol and Other Drug ...
    Feb 19, 2023 · In a 2009 meta-analysis, 53 randomized clinical trials were reviewed, and CBT demonstrated efficacy over all levels of comparator, with effect ...
  124. [124]
    Cognitive Behavioral Interventions for Alcohol and Drug Use Disorders
    Multiple meta analyses and reviews over the past 30 years have concluded that CBT is an effective treatment across a range of substance use disorders (Carroll & ...
  125. [125]
    Motivational interviewing for substance use reduction - PubMed
    Dec 12, 2023 · Authors' conclusions: Motivational interviewing may reduce substance use compared with no intervention up to a short follow-up period. MI ...
  126. [126]
    The Efficacy of Motivational Interviewing with Cognitive Behavioral ...
    Many studies show that combining MI and cognitive behavioral treatment (CBT) as an intervention is more effective for changes in unhealthy behaviors than ...<|separator|>
  127. [127]
    Contingency management treatment for substance use disorders - NIH
    Research on this intervention dates back over 30 years and consistently shows that CM improves drug abuse treatment outcomes (Higgins, Silverman, & Heil, 2008; ...
  128. [128]
    Contingency Management for the Treatment of Substance Use ...
    Nov 14, 2023 · Contingency management (CM) is an evidence-based psychosocial therapy for the treatment of stimulant use disorder, as well as a variety of other substance use ...
  129. [129]
    Contingency Management for Patients Receiving Medication for ...
    Aug 4, 2021 · Contingency management was associated with increased therapy attendance in 5 studies (45%). Studies that targeted therapy attendance and drug ...
  130. [130]
    Mindfulness-Based Interventions for the Treatment of Substance and ...
    The aim of the present paper was to conduct a systematic review about the efficacy of mindfulness-based interventions (MBIs) in both substance and behavioral ...
  131. [131]
    systematic review and meta-analysis of randomized controlled trials
    Oct 18, 2023 · In this systematic review and meta-analysis, we aimed to study the efficacy of MBIs in craving reduction and to synthetize the newly published data.
  132. [132]
    Effects of family therapy for substance abuse: A systematic review of ...
    Dec 23, 2022 · The incorporation of family members in the treatment of substance abuse produces benefits by diminishing consumption and improving family functioning.
  133. [133]
    Family Involvement in Treatment and Recovery for Substance Use ...
    In the past decade several literature reviews and meta-analytic studies have emphasized the top-shelf effectiveness of family-based treatment for SUD across the ...
  134. [134]
    Information about Medications for Opioid Use Disorder (MOUD) - FDA
    Dec 26, 2024 · There are three medications approved by the FDA for the treatment of OUD: buprenorphine, methadone, and naltrexone.
  135. [135]
    Medications for Opioid Use Disorder | National Institute on Drug Abuse
    Mar 20, 2025 · The medication lofexidine helps ease opioid withdrawal symptoms. Medications for opioid use disorder reduce the risk of overdose deaths and of ...
  136. [136]
    Medications for Alcohol Use Disorder - AAFP
    Mar 15, 2016 · Three medications are approved by the US Food and Drug Administration to treat alcohol use disorder: acamprosate, disulfiram, and naltrexone.
  137. [137]
    Pharmacotherapy for Alcohol Use Disorder: A Systematic Review ...
    Nov 7, 2023 · These findings support the use of oral naltrexone at 50 mg/d and acamprosate as first-line pharmacotherapies for alcohol use disorder.
  138. [138]
    What are treatments for tobacco dependence? - NIDA - NIH
    Jan 1, 2020 · FDA-approved pharmacotherapies include various forms of nicotine replacement therapy as well as bupropion and varenicline.
  139. [139]
    FDA-approved medications for smoking cessation - NCBI - NIH
    NRT formulations, Bupropion SR, Varenicline. Gum, Lozenge, Transdermal patch, Nasal spray, Oral inhaler. Product. Nicorette, ZONNIC, Generic.
  140. [140]
    Future pharmacological treatments for substance use disorders - PMC
    This review provides a summary of promising pharmacotherapies for alcohol, opiate, stimulant and nicotine addictions.
  141. [141]
    Pharmacological treatments in pathological gambling - PMC - NIH
    Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Curr Drug Abuse Rev. 2012;5:3–31. doi: 10.2174 ...
  142. [142]
  143. [143]
    Evidence-based pharmacological treatment of substance ... - PubMed
    This review summarizes our current knowledge of the pharmacological treatment of substance use disorders and pathological gambling
  144. [144]
    Medications for Substance Use Disorders - PMC - NIH
    The most effective pharmacotherapies for opiate use disorders are agonist therapies, including methadone and buprenorphine. The authors also examine recent ...
  145. [145]
    Substance use disorders: a comprehensive update of classification ...
    May 9, 2023 · Substance use disorders (SUDs) are highly prevalent and exact a large toll on individuals' health, well‐being, and social functioning.
  146. [146]
    A Contextual Model of Self-Regulation Change Mechanisms among ...
    Aug 24, 2017 · Numerous behavioral treatments for addictive disorders include components explicitly aimed at targeting self-regulation (i.e., coping and ...
  147. [147]
    A randomized controlled trial on a self-guided Internet-based ...
    Jun 22, 2021 · The majority of individuals with problematic and pathological gambling remain untreated, and treatment barriers are high. Internet-based ...
  148. [148]
    Self-directed Technology-Based Therapeutic Methods for Adult ...
    Nov 26, 2021 · This review aims to identify the evidence-based, self-directed, technology-based methods of care that can be used in adult patients after they are discharged ...<|separator|>
  149. [149]
    Find a 12-Step Program For Recovery From Addiction
    Sep 19, 2025 · Although it began with Alcoholics Anonymous (AA), the 12-Step model isn't just for alcohol. Over the years, it has been adapted over the years ...
  150. [150]
    SMART Recovery: Home
    SMART Recovery is the leading evidence-based addiction recovery program. Join a free meeting today and begin experiencing a Life Beyond Addiction.Missing: abstinence | Show results with:abstinence
  151. [151]
    Overcoming Addictions, a Web-Based Application, and SMART ...
    Jul 11, 2013 · Objective: To evaluate the effectiveness of OA and SMART Recovery (SR) with problem drinkers who were new to SMART Recovery. Our experimental ...
  152. [152]
    Abstinence Self-Efficacy and Substance Use at 2 Years - NIH
    Oct 5, 2016 · The relationship between abstinence self-efficacy and substance use at 2 years was examined among a sample (N = 470) of persons with substance use disorders ...
  153. [153]
    High effectiveness of self-help programs after drug addiction therapy
    Aug 23, 2006 · The purpose of this study was to examine whether the use of self-help groups after addiction treatment is associated with higher rates of abstinence.
  154. [154]
    Systematic review of SMART Recovery: Outcomes, process ...
    School of Medicine & Public Health, University of Newcastle. 2 School of Psychology, University of Wollongong. 3 National Drug and Alcohol Research Centre, ...
  155. [155]
    Prioritizing Abstinence-Based Prevention, Regulation, and Recovery ...
    Sep 2, 2025 · Randomized controlled trials (RCTs) comparing manualized AA/TSF to other clinical interventions showed improved rates of continuous abstinence ...
  156. [156]
    Neurobiologic Advances from the Brain Disease Model of Addiction
    Jan 28, 2016 · Factors that increase vulnerability to addiction include family history (presumably through heritability and child-rearing practices), early ...<|control11|><|separator|>
  157. [157]
    People Control Their Addictions - NIH
    The goal of the brain disease model of addiction is to remove any idea of the drinker or drug user as an active participant in their recovery, as someone ...
  158. [158]
    Addiction is driven by excessive goal-directed drug choice under ...
    Jan 6, 2020 · These data suggest that human addiction is primarily driven by excessive goal-directed drug choice under negative affect, and less by habit or compulsion.
  159. [159]
    (PDF) Addiction is not a brain disease - ResearchGate
    Jul 1, 2016 · ' The dominant biomedical model of addiction that conceptualises it as a brain disease has progressively equated addiction with mental illness, ...<|separator|>
  160. [160]
    What Percentage of Addicts Recover? - Recreate Ohio
    Aug 26, 2025 · Nearly 75% of people who experience addiction eventually go on to recover, either with or without formal treatment.
  161. [161]
    Is Addiction Really a Chronic Relapsing Disorder ... - NIH
    Beyond unassisted maturing out in young adults, there is also evidence of natural recovery (i.e., self-directed change without formal treatment) from alcohol ...
  162. [162]
    Review Structural and functional brain recovery in individuals with ...
    Mar 1, 2022 · We performed a systematic review of longitudinal neuroimaging studies to explore putative brain changes associated with abstinence in treatment-seeking ...Review · Introduction · Neurochemical Studies<|control11|><|separator|>
  163. [163]
    Are addictions diseases or choices? - PMC - NIH
    The concept does not have universal support. Particularly widespread is the suspicion that drug use is a choice, even for individuals with long-time substance ...Missing: debate | Show results with:debate
  164. [164]
    Full article: Challenging the brain disease model of addiction
    Nov 10, 2017 · Advocates of addiction as a disorder of choice explicitly state that it is not a free choice for which addicts should be blamed and specifically ...
  165. [165]
    U.S. substance use harm reduction efforts: a review of the current ...
    Jun 8, 2025 · SSPs are effective in reducing transmission of HIV and HCV, reducing injection drug use overall, and increasing the likelihood of individuals ...
  166. [166]
    Syringe exchange programs and harm reduction: New evidence in ...
    I find that SEP openings decrease HIV rates by up to 18.2 percent. However, I present new evidence that SEPs increase rates of opioid-related mortality.
  167. [167]
    MDHHS study finds harm reduction efforts make significant impacts ...
    Sep 25, 2025 · More than 1,650 deaths prevented due to increased access to naloxone. An increase from 135 deaths prevented in 2019 to 569 deaths prevented in ...<|separator|>
  168. [168]
    [PDF] Sweden's successful drug policy: A review of the evidence
    The Swedish drug control policy is guided by the vision and the ultimate goal of achieving a drug- free society and the unequivocal rejection of drugs, their ...Missing: outcomes | Show results with:outcomes<|separator|>
  169. [169]
    “It should be hard to be a drug abuser” An evaluation of the ...
    Drug use was criminalized in Sweden in 1988 with aim of reducing the number of consumers and drug-related risks and harms.
  170. [170]
    Abstinence at Successful Discharge in Publicly Funded Addiction ...
    Only 36% of clients entering treatment reported abstinence at successful discharge. Unfortunately, the existing research on treatment completion and relapse has ...
  171. [171]
    Factors associated with abstinence in addiction inpatient treatment ...
    Jun 20, 2023 · (Citation2016) estimated in their meta-analysis that 35% to 54.4% of individuals with SUD reach remission at least six months after a mean of 17 ...
  172. [172]
    Treating opioid disorder without meds more harmful than no ...
    Dec 19, 2023 · Non-medication-based treatments for opioid use disorder may be more harmful than no treatment at all, a new Yale study finds.
  173. [173]
    [PDF] The Impact of Drug Decriminalization in Portugal
    Furthermore, it registers higher rates of overall and problematic drug use than in both Sweden and the Netherlands, countries having very different ...
  174. [174]
    Drug policy in Sweden: a repressive approach that increases harm.
    Nov 15, 2018 · Sweden has pursued a 'zero-tolerance' approach to drug use, investing heavily in law enforcement, prevention, and abstinence-based treatment.
  175. [175]
    The effectiveness of abstinence‐based and harm reduction‐based ...
    Apr 21, 2024 · Abstinence‐based and harm reduction‐based interventions draw on different causal assumptions about how individuals might address or manage their ...
  176. [176]
    What constitutes effective problematic substance use treatment from ...
    Jan 31, 2020 · Both harm reduction and abstinence-based approaches were considered 'treatment'; and 'effectiveness' was broadly used to mean whatever the ...
  177. [177]
    The Stunning Correlation Between Length of Stay
    Mar 12, 2025 · Only 24.1% of patients who were in treatment for 7 to 20 days were reachable and not using illicit drugs or alcohol one year after leaving ...
  178. [178]
    Evidence-Based Interventions for Preventing Substance Use ...
    The most effective prevention approaches incorporate an understanding that substance use behaviors can fulfill a variety of developmental needs. Therefore, ...
  179. [179]
    Preventing Drug Misuse and Addiction: The Best Strategy - NIDA - NIH
    Jul 6, 2020 · Evidence-based interventions for substance use can save society money in medical costs and help individuals remain productive members of society ...
  180. [180]
    [PDF] Evidence-Based Strategies to Prevent Youth Substance Use - CDC
    Evidence shows that school-based interventions reduce youth substance use, including substance use initiation, and other related behaviors. Approaches in these ...
  181. [181]
    The Action Plan on Alcohol, Tobacco, Drugs and Gambling - THL
    Dec 7, 2023 · Preventive work in substance abuse and addictions is regulated by The Act of organising alcohol, tobacco, drugs and gambling prevention ...<|separator|>
  182. [182]
    Taxation of tobacco, alcohol, and sugar-sweetened beverages - NIH
    Oct 9, 2023 · The article reviews the large body of evidence on how taxation affects the consumption of tobacco, alcohol, and sugar-sweetened beverages (SSB).
  183. [183]
    Public Health Strategies for Tobacco Prevention and Control - CDC
    Mar 28, 2024 · Using evidence-based strategies can reduce tobacco use and eliminate exposure to secondhand smoke. State and local organizations can adopt or ...
  184. [184]
    [PDF] Addictive goods and taxes: A survey from an economic perspective
    In this paper we present an overview of the empirical evidence about the effectiveness of using taxation to influence addictive behaviour, and we address ...<|control11|><|separator|>
  185. [185]
    Policies and interventions to reduce harmful gambling - The Lancet
    Sep 28, 2022 · Focusing on policies and interventions (ie, measures), the aim of this study was to determine if expert consensus could be reached on measures ...
  186. [186]
    Gambling harm prevention and harm reduction in online environments
    Jul 22, 2023 · Online casino games, fast online betting products, and emerging forms of online gambling such as skin betting, are causing an increasing share ...
  187. [187]
    Drug use - the impact of decriminalisation | CityWide
    Drug use rates do not change or dramatically increase when the laws are changed to decriminalise drug use.
  188. [188]
    Oregon shouldn't go backwards on drug decriminalization
    Feb 15, 2024 · There is no evidence that drug use rates in Oregon have increased. A cross-sectional survey of people who use drugs across eight counties in ...
  189. [189]
    Does drug decriminalization increase unintentional drug overdose ...
    Proponents of drug decriminalization argue that it will reduce the stigma associated with drug use so that people using drugs are encouraged to seek treatment, ...
  190. [190]
    Gambling advocacy: lessons from tobacco, alcohol and junk food
    Gambling industry tactics are similar to the tactics of other unhealthy commodity industries. However, advocacy initiatives to counter these tactics in gambling ...